ERA-NET TRANSCAN-3: Translational research on cancer epigenetics

This call of TRANSCAN focuses on: Translational research on cancer epigenetics

The call has two specific aims, and proposals must cover at least one of the specific topics listed below:

Aim 1) The role of epigenetics in cancer initiation and progression

Aim 2) Validation of new epigenetics-based therapeutic strategies to limit cancer progression, prevent relapse/ recurrence or increase the efficiency or reduce toxicity of existing anti-cancer therapies.

Each research consortium must involve a minimum of three (3) and a maximum of six (6) partners, eligible for funding, coming from at least 3 different countries whose funders participate in the call.

Israeli applicants should contact Chief Scientist of the Ministry of Health (Dr. Irit Alon/ Dr. Liron Even- Faitelson) to review and approve submission prior to application. 

Pls. note that in most cases applicants may hold only one MOH grant at any given time. Please check eligibility.

Funding: €140,000 total for Israeli partner + €40,000 for coordination
Duration: 3 years

Research Authority due date: 13.7.23

Pre proposal due date: 21.7.23
Full proposal due date:  15.12.23